vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease. Its drug candidates also include TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase 2b clinical trials for the treatment of type 2 diabetes, as well as initiated Phase 1b/2 clinical trials for the treatment of type 1 diabetes; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. vTv Therapeutics Inc. has a license and research agreement with Calithera Biosciences, Inc. to develop and commercialize its hexokinase II inhibitors for therapeutic, prophylactic, preventative, or diagnostic use. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of vTv Therapeutics Holdings LLC.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VTVT
CUSIPN/A
Phone336-841-0300
Debt
Debt-to-Equity Ratio-0.15
Current Ratio0.19
Quick Ratio0.19
Price-To-Earnings
Trailing P/E Ratio-0.68
Forward P/E Ratio-1.30
P/E GrowthN/A
Sales & Book Value
Annual Sales$290,000.00
Price / Sales134.59
Cash FlowN/A
Price / CashN/A
Book Value($4.60) per share
Price / Book-0.25
Profitability
EPS (Most Recent Fiscal Year)($1.67)
Net Income$-16,140,000.00
Net Margins-292.41%
Return on EquityN/A
Return on Assets-105.28%
Miscellaneous
Employees56
Outstanding Shares34,540,000
Market Cap$43.51 million
vTv Therapeutics (NASDAQ:VTVT) Frequently Asked Questions
What is vTv Therapeutics' stock symbol?
vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT."
How were vTv Therapeutics' earnings last quarter?
vTv Therapeutics Inc (NASDAQ:VTVT) released its quarterly earnings data on Friday, August, 3rd. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by $0.04. The biotechnology company earned $2.47 million during the quarter, compared to analysts' expectations of $2.46 million. View vTv Therapeutics' Earnings History.
When is vTv Therapeutics' next earnings date?
What price target have analysts set for VTVT?
7 analysts have issued 12-month price objectives for vTv Therapeutics' shares. Their predictions range from $4.00 to $28.00. On average, they expect vTv Therapeutics' stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 1,227.4% from the stock's current price. View Analyst Price Targets for vTv Therapeutics.
What is the consensus analysts' recommendation for vTv Therapeutics?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for vTv Therapeutics in the last year. There are currently 6 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for vTv Therapeutics.
Who are some of vTv Therapeutics' key competitors?
Some companies that are related to vTv Therapeutics include Mustang Bio (MBIO), Nature's Sunshine Products Common Stock (NATR), BioDelivery Sciences International (BDSI), Tetraphase Pharmaceuticals (TTPH), Immune Design (IMDZ), Cue Biopharma (CUE), Xenon Pharmaceuticals (XENE), Newron Pharmaceuticals (NWPHF), Syndax Pharmaceuticals (SNDX), Aldeyra Therapeutics (ALDX), Chembio Diagnostics (CEMI), ContraFect (CFRX), LifeVantage (LFVN), Calithera Biosciences (CALA) and Eleven Biotherapeutics (EBIO).
Who are vTv Therapeutics' key executives?
vTv Therapeutics' management team includes the folowing people:
- Mr. Jeffrey B. Kindler, Exec. Chairman (Age 62)
- Mr. Stephen L. Holcombe, Pres & CEO (Age 61)
- Mr. Rudy C. Howard CPA, B.A., CPA, Exec. VP & CFO (Age 60)
- Dr. Larry Douglas Altstiel, Former Exec. VP & Chief Medical Officer (Age 68)
- Dr. Carmen Valcarce Ph.D., Chief Scientific Officer & Exec. VP
When did vTv Therapeutics IPO?
(VTVT) raised $125 million in an IPO on Thursday, July 30th 2015. The company issued 7,800,000 shares at $15.00-$17.00 per share. Piper Jaffray and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.
Has vTv Therapeutics been receiving favorable news coverage?
Media coverage about VTVT stock has trended somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. vTv Therapeutics earned a daily sentiment score of 0.13 on Accern's scale. They also assigned news coverage about the biotechnology company an impact score of 46.63 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term. View Recent Headlines for vTv Therapeutics.
Who are vTv Therapeutics' major shareholders?
vTv Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include MACANDREWS & FORBES INC. (79.80%). Company insiders that own vTv Therapeutics stock include Paul G Savas and Ronald O Perelman. View Institutional Ownership Trends for vTv Therapeutics.
How do I buy shares of vTv Therapeutics?
Shares of VTVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is vTv Therapeutics' stock price today?
One share of VTVT stock can currently be purchased for approximately $1.13.
How big of a company is vTv Therapeutics?
vTv Therapeutics has a market capitalization of $43.51 million and generates $290,000.00 in revenue each year. The biotechnology company earns $-16,140,000.00 in net income (profit) each year or ($1.67) on an earnings per share basis. vTv Therapeutics employs 56 workers across the globe.
How can I contact vTv Therapeutics?
vTv Therapeutics' mailing address is 4170 MENDENHALL OAKS PKWY, HIGH POINT NC, 27265. The biotechnology company can be reached via phone at 336-841-0300 or via email at [email protected]
MarketBeat Community Rating for vTv Therapeutics (NASDAQ VTVT)
MarketBeat's community ratings are surveys of what our community members think about vTv Therapeutics and other stocks. Vote "Outperform" if you believe VTVT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VTVT will underperform the S&P 500 over the long term. You may vote once every thirty days.
